ANX-Vista Partners Comments and ADVENTRX Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference on February 14
In the February Newsletter, Ross Silver, Principal Analyst at Vista Partners states the following regarding ADVENTRX Pharmaceutical, Inc. (NYSE Amex: ANX), "ADVENTRX seems to be bouncing back from year-end tax loss selling and it seems investors are focused on the initiation of two Phase 3 trials scheduled to begin this year. ANX currently trades at a negative enterprise value which means its market cap is less than it cash position. It seems that little to no value is being given to the Company's two late stage clinical candidates. This would seem to make absolutely no sense and we doubt the opportunity to purchase shares of ADVENTRX for less than the company's cash value per share will last for much longer especially considering both Phase 3 trials are fully funded to completion."
To download the FREE February Newsletter, please visit http://www.vistapglobal.com and click the "download newsletter" icon to gain access.
Market Data 
Markets 
AI
